Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Apr 2;215(4):1169–1186. doi: 10.1084/jem.20171285

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Xu et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 1. — Clinical relevance of brain-resident microglia and brain-infiltrating APCs in epileptic brains. (a and b) PET scan demarcates the epileptogenic center (C), and the lesion margin (M) served as internal control for patients RE1 (a) and MTLE3 (b). (c) Number of resting and activated microglia in the epileptogenic center and the lesion margin of patients diagnosed with RE (n = 1), MTLE (n = 1), EM (n = 7), and FCD (n = 17). (d and e) Correlation of seizure frequency with quantity of total (d) or activated microglia (e) in the epileptogenic center of FCD 2 patients. (f) Quantity of resting and activated infiltrating myeloid APCs in the epileptogenic center and the lesion margin of patients diagnosed with RE (n = 1), MTLE (n = 1), EM (n = 7), and FCD (n = 17). (g and h) Correlation of seizure frequency with quantity of total APCs in the epileptogenic center of FCD II (g) and EM (h) patients. ***, P < 0.001. P-values calculated using Student’s t test. R² determined using Pearson’s correlation analysis.